VRTX News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

VR

Mkt Cap

$128.84B

Volume

986.98K

Next Earnings

November 2nd

Chart Financials Earnings News About Insider Filings

Aerska Appoints Laura Sepp-Lorenzino to Scientific Advisory BoardAerska, a biotechnology company developing RNA medicines for CNS diseases through its antibody-oligonucleotide conjugate (AOC) platform, has appointed Laura Sepp-Lorenzino to its Scientific Advisory Board. Sepp-Lorenzino brings over 30 years of experience in genetic medicines and nucleic acid therapies, previously serving as Chief Scientific Officer at Intellia Therapeutics and leading nucleic acid programs at Vertex Pharmaceuticals.GlobeNewswire Inc. · Sep 17, 2026

SION to Cut Workforce by Nearly Half After CF Study Failure, Stock DownSionna Therapeutics announced a 46% workforce reduction and major restructuring following the failure of SION-719 to meet its primary endpoint in a cystic fibrosis study. The company is shifting focus to its dual combination therapy SION-451 + SION-2222, which it plans to advance into phase IIa trials in 2027. The restructuring is expected to extend cash runway into the second half of 2029.Zacks Investment Research · Sep 16, 2026

My Top 5 Favorite Stocks for an Uncertain MarketThe article recommends five resilient stocks suitable for uncertain market conditions: Johnson & Johnson (pharmaceutical and medtech leader with 28 billion-dollar products), Vertex Pharmaceuticals (cystic fibrosis treatment market leader with pipeline expansion), Costco (essential goods retailer with high membership renewal rates), Coca-Cola (beverage company with strong brands and free cash flow), and American Express (payment card company with affluent customer base). These companies offer stability through essential products, strong market positions, and consistent dividend payments.The Motley Fool · Sep 16, 2026

Should You Invest in the VanEck Biotech ETF (BBH)?The VanEck Biotech ETF (BBH) offers low-cost exposure to the biotech sector with a 0.35% expense ratio and $462.7 million in assets. The fund tracks the MVIS US Listed Biotech 25 Index and holds 26 companies with top holdings including Amgen, Gilead Sciences, and Vertex Pharmaceuticals. BBH has returned 21.89% year-to-date and 39.46% over the past year, but carries higher risk with a beta of 0.70 and 19.89% standard deviation. The fund received a Zacks ETF Rank of 2 (Buy).Zacks Investment Research · Sep 16, 2026

AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The article compares AbbVie, a mature pharmaceutical company with stable cash flows and a growing immunology portfolio, against CRISPR Therapeutics, a clinical-stage biotech firm pioneering gene-editing therapies. AbbVie is recommended as the better choice for 2026 due to its profitability, strong free cash flow generation, and rising dividend, while CRISPR offers high-reward potential but faces significant cash burn and execution risks.The Motley Fool · Sep 14, 2026

Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The article compares Amgen, an established pharmaceutical giant with $36.7B in revenue and a 2.60% dividend yield, against CRISPR Therapeutics, a gene-editing biotech pioneer with only $3.5M in revenue but groundbreaking CASGEVY therapy. While CRISPR offers high-growth potential, it remains unprofitable with significant losses. The author recommends Amgen for most investors seeking stability and predictable returns, though acknowledges CRISPR's improving commercial trajectory makes it a more compelling speculative opportunity than previously.The Motley Fool · Sep 11, 2026

Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in SeptemberThe article recommends two pharmaceutical stocks positioned for growth in 2027. CRISPR Therapeutics' Casgevy gene-editing treatment is generating accelerating revenue (78% YoY growth in Q2) and is projected to expand from $40M to $156M in 2027. Viking Therapeutics is entering the GLP-1 weight-loss market with VK2735, offering a monthly injection alternative to weekly competitors and planning oral trials by year-end, with analysts projecting 175% upside potential.The Motley Fool · Sep 11, 2026

Why CRISPR Therapeutics Stock Rocked the Market Last MonthCRISPR Therapeutics stock surged nearly 19% in August following strong Q2 earnings. The company's approved blood disorder treatment Casgevy saw 78% quarter-over-quarter sales growth to $76 million, and the FDA approved its label expansion for pediatric patients aged 2 and older. CRISPR also received a $10 million upfront payment from a licensing deal, significantly boosting revenue to $10.2 million and narrowing net losses compared to year-ago figures.The Motley Fool · Sep 8, 2026

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?The biotech industry is experiencing a strong rebound in 2026. While both Vertex Pharmaceuticals and Regeneron are attractive options, Vertex emerges as the better buy due to its stronger competitive advantage in cystic fibrosis drugs with patent protection until the late 2030s, diversified pipeline targeting high-need areas with less competition, and lower execution risk compared to Regeneron's dependence on weight-loss candidates and defending its Dupixent franchise against increasing competition.The Motley Fool · Sep 4, 2026

3 Stocks Whose Competitive Walls Tower Over Nvidia'sWhile Nvidia has built a strong competitive moat in AI chips, three healthcare stocks—Moderna, Intuitive Surgical, and Vertex Pharmaceuticals—possess even more formidable competitive advantages. Moderna leverages its mRNA expertise across vaccines and oncology; Intuitive Surgical dominates robotic surgery with high switching costs; and Vertex leads in cystic fibrosis treatment with a patent-protected pipeline extending to the late 2030s.The Motley Fool · Sep 3, 2026

VR

VRTXVertex Pharmaceuticals Inc

VRTX

Pay with—

Available Balance0.00

Your PositionYou don't own any VRTX yet.

Related Tickers

Earnings